Zhejiang Hisun Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600267.SS

Zhejiang Hisun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2023: 0.86%

Zhejiang Hisun Pharmaceutical Co., Ltd. Operating Income Margin is 0.86% for the year ending December 31, 2023, a -90.60% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Zhejiang Hisun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2022 was 9.17%, a -3.51% change year over year.
Zhejiang Hisun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2021 was 9.50%, a -20.72% change year over year.
Zhejiang Hisun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2020 was 11.99%, a -49.92% change year over year.
Zhejiang Hisun Pharmaceutical Co., Ltd. Operating Income Margin for the year ending December 31, 2019 was 23.94%, a 2,467.98% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Shanghai Stock Exchange: 600267.SS

Zhejiang Hisun Pharmaceutical Co., Ltd.

CEO	Mr. Weihong Xiao
IPO Date	July 25, 2000
Location	China
Headquarters	No. 46, Waisha Road
Employees	8,062
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Pet Food

Description

Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taizhou, China.

Key trends

Past 5 years